BIOBIJOU Co.,Ltd. (KOSDAQ:489460)
South Korea · Delayed Price · Currency is KRW 10,950
-550 (-4.78%)
At close: Sep 3, 2026
BIOBIJOU Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| 28,558 | 28,491 | 29,633 | 17,130 | |
Revenue Growth | -16.01% | -3.85% | 72.99% | - |
Cost of Revenue | 12,592 | 12,612 | 14,815 | 8,871 |
Gross Profit | 15,966 | 15,879 | 14,819 | 8,259 |
Selling, General & Admin | 9,624 | 10,080 | 3,982 | 2,311 |
Research & Development | 956.1 | 841.97 | 1,213 | 632.7 |
Amortization of Goodwill & Intangibles | 33.08 | 28.6 | 13.84 | 6.53 |
Other Operating Expenses | 73.13 | 64.02 | 47.52 | 29.74 |
Operating Expenses | 10,962 | 11,651 | 5,592 | 3,094 |
Operating Income | 5,004 | 4,227 | 9,227 | 5,165 |
Interest Expense | -18.34 | -38.2 | -444.24 | -594.63 |
Interest & Investment Income | 634.32 | 421.23 | 205.4 | 126.48 |
Currency Exchange Gain (Loss) | 2,197 | 120.88 | 765.23 | 400.31 |
Other Non Operating Income (Expenses) | 19.47 | 14.87 | -922.33 | -949.25 |
EBT Excluding Unusual Items | 7,836 | 4,746 | 8,831 | 4,148 |
Gain (Loss) on Sale of Investments | 290.18 | 249.1 | 148.3 | 79.14 |
Gain (Loss) on Sale of Assets | 3.64 | 3.64 | - | 0.65 |
Pretax Income | 8,130 | 4,999 | 8,979 | 4,227 |
Income Tax Expense | 1,619 | 846.93 | 1,791 | 917.41 |
Earnings From Continuing Operations | 6,511 | 4,152 | 7,188 | 3,310 |
Minority Interest in Earnings | 7.88 | 0.02 | - | - |
Net Income | 6,519 | 4,152 | 7,188 | 3,310 |
Net Income to Common | 6,519 | 4,152 | 7,188 | 3,310 |
Net Income Growth | -16.57% | -42.24% | 117.16% | - |
Shares Outstanding (Basic) | 15 | 14 | 11 | 11 |
Shares Outstanding (Diluted) | 15 | 14 | 11 | 11 |
Shares Change | 23.05% | 21.99% | 6.21% | - |
EPS (Basic) | 432.96 | 298.30 | 630.00 | 308.13 |
EPS (Diluted) | 428.75 | 298.30 | 630.00 | 308.13 |
EPS Growth | -32.20% | -52.65% | 104.46% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | 68.37 | -3,120 | 461.05 | 4,038 |
Free Cash Flow Per Share | 4.50 | -224.14 | 40.41 | 375.87 |
Gross Margin | 55.91% | 55.73% | 50.01% | 48.21% |
Operating Margin | 17.52% | 14.84% | 31.14% | 30.15% |
Profit Margin | 22.83% | 14.57% | 24.26% | 19.32% |
Free Cash Flow Margin | 0.24% | -10.95% | 1.56% | 23.57% |
EBITDA | 5,783 | 5,002 | 9,927 | 5,752 |
EBITDA Margin | 20.25% | 17.56% | 33.50% | 33.58% |
D&A For EBITDA | 779.43 | 774.43 | 700.16 | 587.04 |
EBIT | 5,004 | 4,227 | 9,227 | 5,165 |
EBIT Margin | 17.52% | 14.84% | 31.14% | 30.15% |
Effective Tax Rate | 19.91% | 16.94% | 19.95% | 21.70% |
Advertising Expenses | - | 3,845 | 469.22 | 188.63 |